Oral chemotherapeutic agents: Need of safe medication practice;Sécurisation de l'emploi des chimiothérapies anticancéreuses administrables par voie orale

Pharmacien Hospitalier

Volumn 44, Issue 1, 2009, Pages 36-44

  Ranchon, F ^a   Bouret, C ^a   Charpiat, B ^a   Leboucher, G ^a  

^a CROIX ROUSSE HOSPITAL   (France)

Author keywords

Compliance; Drug interaction; Medication error; Oral antineoplastic agents; Patient information; Patient safety

Indexed keywords

ALTRETAMINE; ANAGRELIDE; ANTINEOPLASTIC AGENT; BEXAROTENE; BUSULFAN; CAPECITABINE; CELLTOP; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; ERLOTINIB; ESTRAMUSTINE PHOSPHATE; ETOPOSIDE; FLUDARABINE PHOSPHATE; GEFITINIB; HYDROXYUREA; IDARUBICIN; IMATINIB; LAPATINIB; LENALIDOMIDE; LOMUSTINE; MELPHALAN; MERCAPTOPURINE; METHOTREXATE; MITOTANE; NAVELBINE; NILOTINIB; PIPOBROMAN; PROCARBAZINE; RETINOIC ACID; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; THALIDOMIDE; TIOGUANINE; UFT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CANCER CHEMOTHERAPY; CLINICAL PROTOCOL; DRUG SAFETY; HUMAN; MEDICATION ERROR; MEDLINE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT EDUCATION; PRESCRIPTION; REVIEW; RISK MANAGEMENT;

EID: 68649118338     PISSN: 07689179     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.phhp.2008.12.002     Document Type: Review

References (60)

1. Hénin E, You B, Tranchand B, Freyer G, Girard P. Les enjeux de l'observance pour les nouvelles chimiothérapies par voie orale : intérêt du modèle pharmacocinétique - pharmacodynamique. Therapie 2007;62:77-85. (Pubitemid 351293209)
2. Blay JY. Les thérapeutiques ciblées du cancer : no lost in translation. Bull Cancer 2006;93:799-804.
3. Fournel-Federico C, You B, Trillet-Lenoir V. Nouvelles thérapeutiques ciblées en oncologie. Rev Prat 2007;57: 2093-2098
4. Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997;15:110-115 (Pubitemid 27021524)
5. Bartel SB. Safe practices and financial considerations in using oral chemotherapeutic agents. Am J Health Syst Pharm 2007;64:S8-14.
6. Weingart SN, Flug J, Brouillard D, et al. Oral chemotherapy safety practices at US cancer centres: questionnaire survey. BMJ 2007;334:407. (Pubitemid 46374648)
7. Levêque D. Expression des posologies des agents anticancéreux en fonction du poids et de la surface corporelle chez l'adulte. Bull Cancer 2007;94:647-651 (Pubitemid 47413886)
8. Taylor JA, Winter L, Geyer LJ, Hawkins DS. Oral outpatient chemotherapy medication errors in children with acute lymphoblastic leukemia. Cancer 2006;107:1400-1406 (Pubitemid 44452791)
9. Moore TJ, Walsh CS, Cohen MR. Reported medication errors associated with methotrexate. Am J Health Syst Pharm 2004;61:1380-1384
10. Harris W. Methotrexate-associated medication errors. Am J Health Syst Pharm 2004;61:2635.
11. Mayor S. UK introduces measures to reduce errors with methotrexate. BMJ 2003;327:70.
12. Viele CS. Managing oral chemotherapy: the healthcare practitioner's role. Am J Health Syst Pharm 2007;64:S25-32.
13. Partridge AH, Avorn J, Wang PS, Winer EP. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 2002;94:652-661 (Pubitemid 34552485)
14. O'Neill VJ, Twelves CJ. Oral cancer treatment: developments in chemotherapy and beyond. Br J Cancer 2002;87:933-937 (Pubitemid 35305640)
15. White-Koning M, Bertozzi-Salamon AI, Vignes M, Arnaud C. L'observance des adolescents atteints de cancer. Bull Cancer 2007;94:349-356
16. Urquhart J. Role of patient compliance in clinical pharmacokinetics. A review of recent research. Clin Pharmacokinet 1994;27:202-215
17. Lai ES, Kuzel T, Lacouture ME. Hand-foot and stump syndrome to sorafenib. J Clin Oncol 2007;25:341-343
18. Laffitte E, Saurat JH. Kinase inhibitor-induced pustules. Dermatology 2005;211:305-306
19. Guillot B, Bessis D. Aspects cliniques et prise en charge des effets secondaires cutanés des inhibiteurs du récepteur à l'EGF. Ann Dermatol Venereol 2006;133:1017-1020 (Pubitemid 46018321)
20. Moore S. Facilitating oral chemotherapy treatment and compliance through patient/family - focused education. Cancer Nurs 2007;30:112-122 (Pubitemid 46573048)
21. e Journées de pharmacovigilance, Lille. Fundamental Clin Pharmacol 2003;17:228.
22. Ropert S, Mir O, Armand JP. Les inhibiteurs oraux de la voie du VEGF. Bull Cancer 2007;94:180-190 (Pubitemid 47401359)
23. Mego M, Reckova M, Obertova J, Sycova-Mila Z, Brozmanova K, Mardiak J. Increased cardiotoxicity of sorafenib in sunitinib pretreated patients with metastatic renal cell carcinoma. Ann Oncol 2007;18:1906-1907 (letter). (Pubitemid 350111579)
24. Christopoulos C, Dimakopoulou V, Rotas E. Primary ovarian insufficiency associated with imatinib therapy. N Eng J Med 2008;358:1079-1080 (Pubitemid 351347122)
25. Rini BI, Tamaskar I, Shaheen P, et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2007;99:81-83
26. Desai J, Yassa L, Marqusee E, et al. Hypothyroidism after sunitinib treatment for patients with gastro-intestinal stromal tumors. Ann Intern Med 2006;145:660-664 (Pubitemid 46768841)
27. Schwiertz V, Bertin C, Henry A, Charpiat B. Number and nature of drug interactions concerning antineoplastic drugs. Bull Cancer 2007;94:477-482
28. Jurus V, Bossaert S, Charpiat B. Estimation du nombre et de la nature des interactions médicamenteuses concernant les médicaments antirétroviraux. J Pharm Clin 2006;25:153-159 (Pubitemid 44520884)
29. Dictionnaire des médicaments Vidal 2008. Version électronique. Date de dernière consultation : 4 mai 2008.
30. Thésaurus de l'Afssaps. http://agmed.sante.gouv.fr/htm/10/ iam/triam.htm. Date de dernière consultation : 4 mai 2008.
31. Martindale: the complete drug reference. Cédérom, version 51. Pharmaceutical Press. Electronic version. Thomson Micromedex. Mise à jour de mars 2008.
32. e ed. 2004. http://www.cnhim.org/.
33. Charpiat B, Allenet B, Roubille R, et al. Facteurs à prendre en compte pour la gestion des interactions médicamenteuses en pratique clinique. Presse Med 2008;37:654-664
34. O'Brien SG, Meinhardt P, Bond E, et al. Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia. Br J Cancer 2003;89:1855-1859.
35. Base de données Thériaque. http://www.theriaque.org/. Date de dernière consultation : 4 mai 2008.
36. Goodin S. Oral chemotherapeutic agents: understanding mechanisms of action and drug interactions. Am J Health Syst Pharm 2007;64:S15-24. (Pubitemid 46676687)
37. Gambillara E, Laffite E, Widmer N, et al. Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukaemia. Dermatology 2005;211:363-365 (Pubitemid 41642114)
38. Grenader T, Gipps M, Shavit L, Gabizon A. Significant drug interaction: phenytoin toxicity due to erlotinib. Lung Cancer 2007;57:404-406 (Pubitemid 47285413)
39. Singh BN, Malhotra BK. Effects of food on the clinical pharmacokinetics of anticancer agents: underlying mechanisms and implications for oral chemotherapy. Clin pharmacokinet 2004;43:1127-1156
40. Reigner B, Verweij J, Dirix L, et al. Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients. Clin Cancer Res 1998;4:941-948 (Pubitemid 28183395)
41. Ling J, Fettner S, Lum BL, Riek M, Rakhit A. Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals. Anticancer Drugs 2008;19:209-216
42. Ratain JM, Cohen EE. The value meal: how to save $1,700 per month or more on lapatinib. J Clin Oncol 2007;25:3397-3398
43. Koch KM, Beelen AP, Ho PTC, Roychowdhury DF. The value of label recommendations: how to dose lapatinib. J Clin Oncol 2007;25:5331-5332 (letter).
44. Messori A. Effect of food on lapatinib pharmacokinetics. J Clin Oncol 2007;25:5332-5333 (letter).
45. Trippoli S. Controversies in using lapatinib at reduced dosage with food. J Clin Oncol 2007;25:5333 (letter). (Pubitemid 350232275)
46. Rahman A, Pazdur R, Wang Y, Huang SM, Lesko L. The value meal: effect of food on lapatinib bioavailability. J Clin Oncol 2007;25:5333-5334 (letter). (Pubitemid 350232276)
47. Ratain MJ, Cohen EE. The value meal: how to save $1,700 per month or more on lapatinib. J Clin Oncol 2007;25:5334-5335 (author reply).
48. Michaud LB, Karpinski JP, Jones KL, Espirito J. Dietary supplements in patients with cancer: risks and key concepts, part 1. Am J Health Syst Pharm 2007;64:369-381 (Pubitemid 46280378)
49. Michaud BL, Karpinski JP, Jones KL, Espirito J. Dietary supplements in patients with cancer: risks and key concepts, part 2. Am J Health Syst Pharm 2007;64:467-480 (Pubitemid 46339260)
50. Simon L, Prebay D, Beretz A, et al. Médecines complé mentaires et alternatives suivies par les patients cancéreux en France. Bull Cancer 2007;94:483-488 (Pubitemid 46981012)
51. Smith PF, Bullock JM, Booker BM, Haas CE, Berenson C, Jusko WJ. Induction of imatinib metabolism by hypericum perforatum. Blood 2004;104:1229-1230 (letter). (Pubitemid 39038051)
52. Reif S, Nicolson MC, Bisset D, et al. Effect of grapefruit juice intake on etoposide bioavailability. Eur J Clin Pharmacol 2002;58:491-494 (Pubitemid 35244924)
53. American Society of Health-System Pharmacists. ASHP guidelines on preventing medication errors with antineoplastic agents. Am J Hosp Pharm 2002;59:1648-1668
54. American Society of Health-System Pharmacists. ASHP Guidelines on pharmacist-conducted patient education and counseling. Am J Health Syst Pharm 1997;54:431-434
55. Pérol D, Toutenu P, Lefranc A, et al. L'éducation thérapeutique en cancérologie : vers une reconnaissance des compétences du patient. Bull Cancer 2007;94:267-274 (Pubitemid 46586779)
56. Anonyme. The Erice manifesto: for global reform of the safety of medicines in patient care. Drug Saf 2007;30:187-190
57. RCP géfitinib. Document du laboratoire Astra Zeneca. Révisé en novembre 2007.
58. RCP lapatinib. Document du laboratoire GSK, mars 2007.
59. RCP nilotinib. Document du laboratoire Novartis, février 2008.
60. RCP sunitinib. Document du laboratoire Pfizer, juillet 2006.